Análisis Argos
CNP
CNPSin veredicto2 señales de riesgo
CenterPoint Energy, Inc. · Utilities
US$ 44.10
precio al 2026-07-28
Valor justo Argos*
US$ 32
vs. su valor justo
−28%
Score Argos
23/100
Sin veredicto
LA RESPUESTA
No tenemos un veredicto de valuación confiable acá: su flujo de caja no permite una estimación sólida. Mirá su calidad y su salud para formarte una idea — preferimos eso a inventarte un número.
Recompensas
Sin recompensas destacadas.
Riesgos
!Cotiza 28% por encima de su valor justo.
!Balance frágil: la deuda pesa sobre el negocio.
!Crecimiento estancado o en baja.
!Altman Z'' en zona roja (0.67)
VALOR1/6FUTURO2/6PASADO2/6SALUD1/6DIVIDENDO3/6
El Iris de calidad
VALOR1/6FUTURO2/6PASADO2/6SALUD1/6DIVIDENDO3/6
ValorCotiza por encima de su valor justo
FuturoCrecimiento moderado
PasadoHistorial aceptable
SaludBalance frágil
DividendoRetorno al accionista moderado
Score Argos23de 100Sin veredicto
Ingresos8%
US$ 9.4 B
Margen operativo2%
22.5%
Flujo de caja libre0%
US$ -2.4 B
Deuda neta
US$ 23.6 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 28.8B
P/E27.4x
EV/EBITDA14.4x
FCF yield-8.3%
ROIC5.1%
Margen operativo22.5%
Crecim. ingresos+8.3%/año
Piotroski F4/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

seekingalpha.com · 11 jul
2 Retirement Income Powerhouses For Inflationary Times
Persistent, structurally elevated inflation necessitates repositioning portfolios toward higher-yielding, inflation-resilient income products. The risk is that on a real portfolio income growth basis, the necessary wealth accumulation (or preservation) won't simply be there. Yet we have to be cognizant of not falling into the other extreme of elevated NAV destruction or dividend cut risks.
reuters.com · 9 jul
US power companies scramble to secure equipment as surging data center demand strains supplies
Skyrocketing demand from artificial intelligence data centers is exacerbating shortages of critical grid equipment like transformers across the U.S., driving up costs, stretching out wait times and spurring utilities ​and developers to lock in orders far in advance.
globenewswire.com · 7 jul
CenterPoint Energy, Inc. to Host Webcast of Second Quarter 2026 Earnings Conference Call on July 28, 2026
Houston, TX, July 07, 2026 (GLOBE NEWSWIRE) -- CenterPoint Energy, Inc. (NYSE:CNP) announces the following webcast - - Date:  July 7, 2026 Time: 5:00 PM ET Listen via Internet:  http://investors.centerpointenergy.com/ Click the link "CenterPoint Energy, Inc. Second Quarter 2026 Earnings Conference Call Webcast" Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=71418&k=8861E677
globenewswire.com · 7 jul
CenterPoint Energy, Inc. to Host Webcast of Second Quarter 2026 Earnings Conference Call on July 28, 2026
Houston, TX, July 07, 2026 (GLOBE NEWSWIRE) -- CenterPoint Energy, Inc. (NYSE: CNP) announces the following webcast - - Date: July 7, 2026 Time: 5:00 PM ET Listen via Internet: http://investors. centerpointenergy. com/ Click the link "CenterPoint Energy, Inc. Second Quarter 2026 Earnings Conference Call Webcast" Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.
globenewswire.com · 30 jun
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements in tibial-femoral angle (TFA). As previously reported, improvements in annualized growth velocity were maintained and ACH-specific height Z-score increased with TransCon CNP treatment through Week 104. The data were presented by Leanne M. Ward, M.D., FRCPC, Professor of Pediatrics at the University of Ottawa and Children's Hospital of Eastern Ontario, during the 12th International Conference on Children's Bone Health (ICCBH 2026) held in Montreal, Canada.
zacks.com · 23 jun
CNP vs. ES: Which Utility Stock Offers Better Return Potential?
CenterPoint Energy and Eversource Energy both benefit from rising power demand and grid investments, but debt, ROE, dividends and price gains set up a sharper utility stock comparison.
zacks.com · 13 jun
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does CenterPoint (CNP) have what it takes?
fool.com · 11 jun
Algonquin Power & Utilities vs. CenterPoint Energy: Which Utilities Stock Is a Better Buy in 2026?
Revenue growth, profit margins, and risk profiles set these two utility giants apart, here's how their financials and valuations stack up for 2026 portfolios.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.